X0306 4 2020-04-03 0 0001566044 Menlo Therapeutics Inc. MNLO 0001417397 Basta Steven L 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 1 0 0 0 Common Stock 2020-04-03 4 A 0 14499 A 536537 D As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares. /s/ Mutya Harsch, attorney-in-fact for Steven Basta 2020-04-07